Automate Your Wheel Strategy on SGHT
With Tiblio's Option Bot, you can configure your own wheel strategy including SGHT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SGHT
- Rev/Share 1.4724
- Book/Share 1.351
- PB 3.0496
- Debt/Equity 0.5795
- CurrentRatio 10.0059
- ROIC -0.4428
- MktCap 215753688.0
- FreeCF/Share -0.4323
- PFCF -9.6297
- PE -4.3566
- Debt/Assets 0.3326
- DivYield 0
- ROE -0.5938
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SGHT | Lake Street | Hold | Buy | -- | $5 | Aug. 8, 2025 |
| Initiation | SGHT | UBS | -- | Buy | -- | $5.5 | Dec. 6, 2024 |
| Initiation | SGHT | Lake Street | -- | Buy | -- | $10 | Aug. 21, 2024 |
News
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
SGHT
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research
Read More
About Sight Sciences, Inc. (SGHT)
- IPO Date 2021-07-15
- Website https://www.sightsciences.com
- Industry Medical - Devices
- CEO Paul Badawi
- Employees 216
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.